Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:21:06.428Z.
Consensus retrieved: 2026-10-06T09:52:17.023Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:21:06.428Z.
Quote observation: 2026-10-06T19:20:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e0d40f2287a6df540829b60f0e5c7cec39727eaf24e7e990ba5054a2dfdba9d9
Forward PE Ratio (N/A) = Dated Quote Price ($7.65) / Consensus Forward EPS ($-1.54)
FORWARD PE RATIO
N/A
Capricor Therapeutics, Inc.
Market Cap
$439.96M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Capricor Therapeutics, Inc. (CAPR) | $439.96M | N/A |
| NeuroPace, Inc. (NPCE)vs › | $440.69M | N/A |
| Assembly Biosciences, Inc. (ASMB)vs › | $439.02M | N/A |
| Tectonic Therapeutic, Inc. (TECX)vs › | $436.95M | N/A |
| Ovid Therapeutics Inc. (OVID)vs › | $448.53M | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $448.85M | N/A |
| Editas Medicine, Inc. (EDIT)vs › | $428.93M | N/A |
| NRC Health (NRC)vs › | $453.44M | 22.86 |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $426.51M | N/A |
| NeoGenomics, Inc. (NEO)vs › | $426.02M | 90.73 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $7.65, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.54 | $-2.48 – $1.53 | 8 | n/m |
| 2027-12-31 | $-1.49 | $-3.56 – $0.78 | 8 | n/m |
| 2028-12-31 | $0.16 | $-2.27 – $3.86 | 5 | 47.2x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
